getting paid seems to be an issue for them. When investors look at the medical space generally, this isn’t something they see as a risk. So this is a big negative associated with the countries they operate in.
discounted rights issue coming to force existing holders to dip into their wallets. I agree with Wilbur’s comments above, no point selling even if you could get out
Ann: 2022 Q4 Quarterly Activities Report and Appendix 4C, page-5
-
- There are more pages in this discussion • 5 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IME (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
42.0¢ |
Change
0.015(3.70%) |
Mkt cap ! $19.12M | |||
| Open | High | Low | Value | Volume |
| 41.5¢ | 42.0¢ | 39.0¢ | $15.94K | 39.45K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 16200 | 40.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 44.0¢ | 20000 | 1 |
View Market Depth
| Last trade - 14.59pm 19/06/2024 (20 minute delay) ? |
| IME (ASX) Chart |